{"disease":{"id":"injection","name":"injection"},"drugs":{"marketed":[{"drug_id":"sterile-water-for-injection","indication_name":"Dilution or Dissolution for Injection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sterile Water","generic_name":"Sterile Water For Injection","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (subcutaneous injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age) (0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"razoxane","indication_name":"Extravasation Injury from Anthracycline Injection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razoxin","generic_name":"RAZOXANE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue."},{"drug_id":"vaccination","indication_name":"injection site pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Post - Vaccination","generic_name":"vaccination","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"Inactivated Poliovirus Vaccine [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dexrazoxane","indication_name":"Extravasation Injury from Anthracycline Injection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinecard","generic_name":"DEXRAZOXANE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Cytoprotective Agent","quality_score":10,"revenue":null,"mechanism":"Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment."},{"drug_id":"zinecard","indication_name":"Extravasation Injury from Anthracycline Injection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zinecard","company_name":"M.D. Anderson Cancer Center","drug_phase":"phase_1","molecular_target":"DNA topoisomerase 2-beta, DNA topoisomerase 2-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03635268","title":"Endophthalmitis After Intravitreal Injection of Antiangiogenic Agents or Corticosteroids, a Cohort Study of the French Population of Patients Who Received Injections Over 9 Years","phase":"","overall_status":"COMPLETED","enrollment_count":360000,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT06810011","title":"Eye Diseases \"Treated\" With Interoperable Medical Informatics","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital Muenster","has_results":false},{"nct_id":"NCT07257250","title":"Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Mỹ Đức Hospital","has_results":false},{"nct_id":"NCT04421599","title":"Necessity of Aspiration in the Ventrogluteal Site","phase":"NA","overall_status":"UNKNOWN","enrollment_count":834,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT03183908","title":"FLUAD® vs. Fluzone® High-Dose Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":757,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT04751084","title":"Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":675,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06339645","title":"Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study","phase":"","overall_status":"UNKNOWN","enrollment_count":658,"lead_sponsor_name":"Hualien Tzu Chi General Hospital","has_results":false},{"nct_id":"NCT05688423","title":"Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03033563","title":"ICSI Outcome of Ejaculated Versus Extracted Testicular Spermatozoa","phase":"","overall_status":"COMPLETED","enrollment_count":430,"lead_sponsor_name":"Adam International Hospital","has_results":false},{"nct_id":"NCT05157230","title":"Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination","phase":"NA","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"Bursa Yuksek Ihtisas Training and Research Hospital","has_results":false},{"nct_id":"NCT03949764","title":"The Kentucky Viral Hepatitis Treatment Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Jennifer Havens","has_results":false},{"nct_id":"NCT03511846","title":"Pain Biomarker Study","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":371,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT04311099","title":"Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Claus Anders Bertelsen, PhD, MD","has_results":false},{"nct_id":"NCT05028361","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT03569215","title":"Psychiatric Disorders With Prolonged Infertility","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT03088631","title":"Metformin in Intracytoplasmic Sperm Injection Cycles","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04427202","title":"Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)","phase":"NA","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT06513156","title":"Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use","phase":"NA","overall_status":"RECRUITING","enrollment_count":304,"lead_sponsor_name":"Elana Rosenthal","has_results":false},{"nct_id":"NCT06220370","title":"PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Kirby Institute","has_results":false},{"nct_id":"NCT06651788","title":"Does Ethyl Chloride Spray Work?","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05157191","title":"Safety of Pediatric COVID-19 Vaccination","phase":"","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06762665","title":"RAdiology Consultation Effectiveness","phase":"NA","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05007041","title":"Simultaneous RZV and aIIV4 Vaccination","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT04219332","title":"Randomized Controlled Trial on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":266,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03680690","title":"Pregnancy Rate in Women With Normal Uterine Cavity and Those With Corrected Uterine Lesions in ICSI Cycles","phase":"","overall_status":"UNKNOWN","enrollment_count":244,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05956054","title":"A Comparison of Intravascular Penetration With Curved Needle and Straight Needle During S1 STE","phase":"NA","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Kyungpook National University Chilgok Hospital","has_results":false},{"nct_id":"NCT06493136","title":"Etude de l'ANesthésie Par Gel de Lidocaïne Pour Les Injections IntrA vitréennes","phase":"","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Institut Ophtalmologique de l'Ouest Jules Verne","has_results":false},{"nct_id":"NCT03220555","title":"Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center","phase":"NA","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05886972","title":"Effect Of Patient Awareness About Possibility Of Occurrence Of Pain During Propofol Injection On The Rate Of Incidence And Severity Of Pain During Injection .","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT03914183","title":"Can mCPN Intervention Improve Injection Site Rotation","phase":"NA","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Pink Pearls Inc","has_results":false},{"nct_id":"NCT03376763","title":"MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Korea Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06468163","title":"Efficacy of Local Antibiotic Injection Via a Catheter for Treating Acute Periprosthetic Infections After Knee DAIR Surgery","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Xinjiang Medical University","has_results":false},{"nct_id":"NCT05819450","title":"Sonography-Guided Volumetric Rejuvenation on Dorsal Hands","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06430515","title":"The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT07203521","title":"RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":194,"lead_sponsor_name":"Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT07220382","title":"Preoperative BOTOX® Injection for Large Ventral Hernia Repair","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03145519","title":"A Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population","phase":"NA","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Optomeditech Oy","has_results":false},{"nct_id":"NCT07285980","title":"Comparison of Bier Block and Lidocaine-Propofol Mixture for Prevention of Propofol Injection Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Asma Ladib","has_results":false},{"nct_id":"NCT04767737","title":"The Effect of Aromatherapy on the Insulin Injection Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Karadeniz Technical University","has_results":false},{"nct_id":"NCT05563233","title":"ShotBloker and Helfer Skin Tap Technique During Intramuscular Injection in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Tarsus University","has_results":false},{"nct_id":"NCT07262463","title":"Effect of Traction-Pressure-Release and Manual Pressure on Intramuscular Injection Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Melek Sahin","has_results":false},{"nct_id":"NCT07301775","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Ahmad Zeeshan Jamil","has_results":false},{"nct_id":"NCT03645369","title":"Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin Injection","phase":"NA","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Istanbul Saglik Bilimleri University","has_results":false},{"nct_id":"NCT06275529","title":"Evaluation of Transforaminal Epidural Steroid Injection in Radicular Low Back Pain According to MSU Classification","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Başakşehir Çam & Sakura City Hospital","has_results":false},{"nct_id":"NCT04436666","title":"Virtual Reality, Ice Application and Self-injection and Self-test Fair, Pain and State Anxiety","phase":"NA","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT05833646","title":"Comparison of the Effects of ShotBlocker, Virtual Reality Glasses and Cold Application in Subcutaneous Heparin Injection","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Ankara Yildirim Beyazıt University","has_results":false},{"nct_id":"NCT05581433","title":"Vapocoolant Spray Application During Intraarticular Knee Injection","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Istanbul Rumeli University","has_results":false},{"nct_id":"NCT03583749","title":"Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06793618","title":"Effectiveness of the Z-Track Technique As a Pain-Reducing Strategy for Neonates During Intramuscular Injection: a Randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"University of Baghdad","has_results":false},{"nct_id":"NCT05495542","title":"The Effect of ShotBlocker on Injection Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Bornova No. 25 Mevlana Family Health Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}